Medical device maker Abiomed (NASDAQ:ABMD) reported great results for the second quarter of fiscal 2013 today, but despite strong revenue growth, the stock took a massive 30% plunge.

In the following video, health care analysts Max Macaluso and David Williamson discuss Abiomed's earnings report and the reasons behind today's dramatic decline.

Max Macaluso, Ph.D. and David Williamson have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.